SCYNEXIS Inc is drug development company which focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing lead product candidate, SCY-078 which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The SCY-078 is a novel and structurally distinct triterpenoid glucan synthase inhibitor which is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.